Lexology November 13, 2023
As discussed here and here, the psychedelic renaissance has spurred a renewed interest in the potential therapeutic benefits of substances such as psilocybin, LSD and tryptamines. As the evidence of clinical efficacy builds, countries are now grappling with how to legalize the substances for medical treatment, yet still restrict illicit use of the drugs. In this article, we will summarize how Canada, the United States (US) and the European Union (EU) are regulating such drugs and are allowing them to be used in clinical trials. In addition, we will provide a brief overview of recent developments in Australia where medicines containing MDMA or psilocybin can be legally prescribed for limited purposes.
Canada
Currently, there are no licensed commercial therapeutic products...
Today's Sponsors
Today's Sponsor